Patent ID: 6727278
Filing Date: 2004-04-27
Classification: A61K,C07H,G01N

Abstract:
A composition comprising (a) an amyloid fibril inhibitory effective amount of a compound that inhibits formation of amyloid fibrils when administered, at an in-tissue concentration of about 10âˆ’5 or less, to a test animal that has received an intracerebral injection of DMS wherein said compound is selected from the group consisting of pyrimethamin, cromolyn sodium, erythyromycin, purpurogallin, tartrazine, sulfanilamide, benzopurpurine, benzopurpurine 4B, 29H, 31H-phthalocyanine, 5-methyl-2-thiouridine and 1,2-benzylsoxazole and (b) a pharmaceutically acceptable carrier, wherein said composition is capable of crossing the blood-brain barrier.